2024-512097-98-00招募中2 期
An open-label dose escalation study to evaluate safety, tolerability, biodistribution and efficacy of [90Y]Y-PentixaTher for the therapy of recurrent or refractory primary or isolated secondary central nervous system lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Incidence, severity and relationship of (S)AEs (graded in severity according to NCI CTCAE version 5.0)
研究概览
简要总结
- To assess the safety and tolerability of different doses of endoradiotherapy (ERT) with [90Y]Y-PentixaTher [90Y-PTT] administered once in patients with C-X-C chemokine receptor 4 (CXCR4)-positive primary or isolated secondary central nervous system (CNS) lymphoma.
- To determine a recommended phase 2 dose.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Entire trial period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent, by the patient or an authorized legal guardian in case the patient is temporarily not competent due to his or her disease, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- •For male patient whose partner is of child-bearing potential: patient is willing to ensure that he and his partner use effective contraception during the study and for six months after 90Y-PTT treatment.
- •ECOG performance status ≤
- •Confirmed presence of CXCR4 on technically evaluable tumor lesions documented by a visually CXCR4-positive [68Ga]Ga-PentixaFor PET scan within two months prior to enrolment in the study or during Screening.
- •Blood test results as follows: a. Absolute neutrophil count: > 1.0 x 10^9 /L b. Hemoglobin: ≥ 8 g/dL c. Platelets: ≥ 75 x 10^9/L d. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP): ≤ 3 x ULN (upper limit of normal) e. Serum creatinine: ≤ 2 x ULN and Cockroft Gault calculated glomerular filtration rate (GFR) ≥ 50 mL/min f. Bilirubin: ≤ 3 x ULN.
- •Patients of either gender aged > 18 years.
- •Body weight ≤ 180 kg.
- •At least one measurable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the brain parenchyma or measurable meningeal lesion.
- •Histologically, cytologically, radiologically or by detection of ctDNA mutation (MYD88/L265P) in cerebrospinal fluid confirmed relapsed/refractory PCNSL or relapsed/refractory SCNSL. Initial histologic confirmation at first diagnosis is mandatory. No peripheral lymphoma evidence is allowed.
- •Recurrent or refractory CNSL a) For recurrent disease, comprising new lesions or recurrent CNSL after a CR at that site, there are no maximum number of recurrences. b) Refractory CNSL comprises patients with non-responding CNSL to frontline therapy, or progressive disease after an initial,partial response (PR).
- •Stored stem cells with at least ≥ 2 x 10^6 CD34+ cells/kg of body weight.
- •If sexually active female patient of childbearing potential: patient agrees to take adequate contraceptive measures during study participation and agrees to continue use of this method for the duration of the study and for six months after the last dose.
- •Female patient without childbearing potential: documented history (e.g., tubal ligation or hysterectomy) or is post-menopausal.
排除标准
- •Known or suspected hypersensitivity to study product(s) or related products.
- •Participation in any other clinical study of an approved or non-approved IMP within the last 30 days (or ≤ 5 terminal elimination half-lives of previous IMP, whichever is longer) before screening.
- •Any disorder (e.g., unstable angina pectoris, cardiac arrhythmia (excluding atrial fibrillation and atrial flutter, uncontrolled congestive heart failure), poorly controlled hypertension, poorly controlled diabetes mellitus [HbA1c ≥ 9%], etc.) or laboratory findings, except for conditions associated with CNS lymphoma, which in the investigator's opinion might jeopardize patient's safety or compliance with the protocol.
- •Presence of active infection, or history of serious infection six weeks prior to IMP administration. Patients with uncontrolled human immunodeficiency virus (HIV) infection as well as acute or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are excluded (Note: Patients on antiretroviral therapy (ART) with controlled HIV infection (defined as sufficient ART compliance, non-measurable HIV and CD4+ T helper cells > 200/microL) may be enrolled, if considered eligible for study treatment by the investigator.).
- •SCNSL with systemic involvement.
- •Brain radiation therapy ≤ 180 days before IMP infusion.
- •Any mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study, and/or evidence of an uncooperative attitude without designated legal representative.
- •Contraindication for contrast-enhanced MRI as set out in the relevant institutional guidelines (e.g., pacemaker, defibrillator, aneurysm clip, metal in the body, renal insufficiency, severe claustrophobia etc.) or contraindication for the use of gadolinium contrast for MRI.
- •Previous treatment with the IMP.
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). A pregnancy test will be performed at the start of the study for all female patients of childbearing potential (i.e., not surgically sterile or two years postmenopausal).
- •Male of reproductive age who or whose partner(s) is not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice).
结局指标
主要结局
Incidence, severity and relationship of (S)AEs (graded in severity according to NCI CTCAE version 5.0)
Incidence, severity and relationship of (S)AEs (graded in severity according to NCI CTCAE version 5.0)
Incidence and severity of DLT
Incidence and severity of DLT
Changes from baseline in vital signs.
Changes from baseline in vital signs.
Changes from baseline in laboratory parameters (hematology and biochemistry, urinalysis).
Changes from baseline in laboratory parameters (hematology and biochemistry, urinalysis).
Abnormal findings in physical examination
Abnormal findings in physical examination
Findings 12-lead ECG
Findings 12-lead ECG
SCT after treatment
SCT after treatment
Mortality rate at 30 and 90 days post-treatment
Mortality rate at 30 and 90 days post-treatment
次要结局
- Biodistribution: • Maximal uptake (%) for tumor lesion • Maximal uptake (%) in discernible organs • TAC in discernible thoracic and abdominal organs, target lesion and blood • AUC of 90Y-PTT in discernible thoracic and abdominal organs, target lesion and blood • AUC of 90Y-PTT in urine
- Radiation dosimetry: • Organ receiving the highest absorbed dose • Specific absorbed dose per organ and for target lesion • Cumulative absorbed organ/lesion doses
- Efficacy • ORR at one month and three months • PFS at one month and three months • Rate of CR and PR at one month and three months • PFS at 12 month • OS at one month, 3 months, 12 months
研究者
Clinical trial team
Scientific
Pentixapharm AG
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsColorectal CancerPancreatic CancerNon-Small Cell Lung CancerNCT07300150PAQ Therapeutics, Inc.210
招募中
2 期
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer2022-502774-17-00AstraZeneca AB95
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)NCT07282847AskBio Inc12
招募中
2 期
GEN1047 for Solid Tumors - First in Human (FIH) Trial2024-510722-10-00Genmab A/S268
招募中
2 期
A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors2023-504139-42-00AstraZeneca AB48